Evidence map›Paper›PMID 39730300›Full record

SynthesisClinical lymphoma, myeloma & leukemia2025

Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review.

Yimeng Li, Sylvia H Hsu, Rong Wang, Poy Theprungsirikul, Natalia Neparidze, Su-Hsin Chang, Shi-Yi Wang

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Clinical lymphoma, myeloma & leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance.Journal of the advanced practitioner in oncology · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yimeng LiDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.
Sylvia H HsuSchulich School of Business, York University, Toronto, Canada.
Rong WangDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT.
Poy TheprungsirikulCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT.
Natalia NeparidzeCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT.
Su-Hsin ChangDivision of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO.
Shi-Yi WangDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT. Electronic address: shiyi.wang@yale.edu.

Funding

Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reductionU01CA265735 · NCI · WASHINGTON UNIVERSITY · PI CHANG, SU-HSIN, WANG, SHIYI · 2021 to 2025
$3.2M
NCI NIH HHS U01 CA265735
6 · The paper itself

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition of multiple myeloma (MM). Evidence suggested old age, black race, male gender, and obesity as risk factors for MGUS development; however, whether they are associated with an increased risk of progression to MM among patients with MGUS is unclear. A systematic search of PUBMED and EMBASE for cohort studies investigating the association between age/race/gender/obesity and progression to MM. We used the Newcastle-Ottawa Scale (NOS) to assess the methodologic quality of the included studies. Summary risk ratios were calculated using random-effects models. We identified 24 publications, of which 17 articles were included in the main analyses. Overall, the quality of the studies was fair (mean NOS = 5.5). Our meta-analyses showed that old age was positively associated with the risk of the MGUS-MM progression (risk ratio: 2.38; 95% confidence interval [CI] 1.59-3.57), while race was not statistically significantly associated with the risk (blacks vs whites: 1.09; 95% CI: 0.77-1.54). Males had a lower risk of MGUS-MM progression, compared to females (risk ratio: 0.70; 95% CI 0.50-1.0; P-value = .048). High body mass index was significantly associated with an increased risk of MGUS-MM progression (risk ratio: 1.32; 95% CI 1.12-1.57). Based on extant research, old age, female sex, and obesity may be implicated in MGUS-MM progression. However, several studies which found an insignificant association between age/gender and progression did not report the risk estimates. Publication bias exists and our risk estimates may be overestimated. More studies are warranted to confirm our findings.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaAgedDisease ProgressionFemaleHumansMaleRisk FactorsBMIGenderObesityRaceSystematic review

Identifiers

PMID39730300
PMCPMC11911095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.